Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical — Corporate Update (February 2020)

17 slides from Biohaven Pharmaceutical's corporate update, Feb 28, 2020

  1. Slide 1: Nurtec ODT Investor Webcast

    Slide 1: Nurtec ODT Investor Webcast

    © 2018 Biohaven Pharmaceuticals. All rights reserved. Nurtec™ ODT Investor Webcast FEBRUARY 28, 2020NYSE: BHVN

  2. Slide 2: Now FDA Approved

    Slide 2: Now FDA Approved

    Now FDA Approved 2 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

  3. Slide 3: Nurtec ODT: One Dose, Anytime, Anywhere

    Slide 3: Nurtec ODT: One Dose, Anytime, Anywhere

    Sustained response up to 48 hours. Half-life of 11 hours. One Dose. Anytime. Anywhere. No titration needed. Quick-dissolve ODT can start working in minutes IMPORTANT SAFETY INFORMATION Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions: If a serious

  4. Slide 4: Now FDA Approved 4 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Slide 4: Now FDA Approved 4 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Now FDA Approved 4 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

  5. Slide 5: Migraine Significantly Impairs Patients' Lives

    Slide 5: Migraine Significantly Impairs Patients' Lives

    Migraine Significantly Impairs Patient’s Lives Migraine affects ~15% of the US population1 with prevalence highest during peak employment years (25–55 years of age)3 1 in 5 women2 20,000 per 100,000 women 1 in 16 men2 6,250 per 100,000 men • • Chronic neurological disease characterized by disabling

  6. Slide 6: Migraine Attacks: A Leading Cause of Economic Burden

    Slide 6: Migraine Attacks: A Leading Cause of Economic Burden

    Migraine Attacks: A Leading Cause of Economic Burden in US costs for migraine in the US are estimated at $27 BILLION1 Annual total ~25% OF ER VISITS FOR MIGRAINE were followed by a second ER visit for headache in <6 months2 In a study of over 850,000 patients with migraine, patients with 2 or more m

  7. Slide 7: Now FDA Approved 7 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Slide 7: Now FDA Approved 7 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Now FDA Approved 7 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

  8. Slide 8: FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 8

    Slide 8: FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 8

    FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 8

  9. Slide 9: One dose rimegepant 75 mg ODT delivered superior efficacy vs placebo across 21 endpoints

    Slide 9: One dose rimegepant 75 mg ODT delivered superior efficacy vs placebo across 21 endpoints

    One dose rimegepant 75 mg ODT delivered superior efficacy vs placebo across a broad-spectrum of 21 hierarchically tested endpoints1 sk Freedom from MBS,2 hrs 35.1 26.8 • Ability to function normally, 2 hrs Sustained pain relief,2-24 hrs 38.1 47.8 25.8 27.7 No rescue medication within 24 hrs 70.8 16.

  10. Slide 10: No individual adverse event had an incidence greater than 2%

    Slide 10: No individual adverse event had an incidence greater than 2%

    2% No individual AE had an incidence greater than 2%1;3* IMPORTANT SAFETY INFORMATION Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious

  11. Slide 11: Now FDA Approved 11 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Slide 11: Now FDA Approved 11 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Now FDA Approved 11 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

  12. Slide 12: ICER report on cost effectiveness of rimegepant

    Slide 12: ICER report on cost effectiveness of rimegepant

    “In our analysis of the cost effectiveness…we found that for patients not tolerated, or cost effective at for whom triptans are not effective, are contraindicated…rimegepant…[is] commonly used thresholds.” 25th ICER Report Feb 2020, Page ES18 Atlas S, Touchette D, Agboola F, Lee T, Chapman R, Pearso

  13. Slide 13: Nurtec ODT blister pack instructions

    Slide 13: Nurtec ODT blister pack instructions

    Now FDA PEEL....HERE Approved INSTRUCTIONS PEEL....HERE PEEL.A.HERE btohoven .. PEEL....HERE btohoven pharmaceuticals NURTECTN OOT {rimegepant) orally disintegrating tablets 75me Lot Exp; btohoven pharmoc90tic:ats NURTECTN OOT {rimegepantl orally disintegrating tablets 75mg Lot Exp; biOhov.n pharmac

  14. Slide 14: Now FDA Approved 14 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Slide 14: Now FDA Approved 14 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Now FDA Approved 14 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

  15. Slide 15: ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Slide 15: ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

  16. Slide 16: Now FDA Approved 16 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Slide 16: Now FDA Approved 16 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

    Now FDA Approved 16 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

  17. Slide 17: Nurtec ODT blister pack instructions

    Slide 17: Nurtec ODT blister pack instructions

    Now FDA PEEL....HERE Approved INSTRUCTIONS PEEL....HERE PEEL.A.HERE btohoven .. PEEL....HERE btohoven pharmaceuticals NURTECTN OOT {rimegepant) orally disintegrating tablets 75me Lot Exp; btohoven pharmoc90tic:ats NURTECTN OOT {rimegepantl orally disintegrating tablets 75mg Lot Exp; biOhov.n pharmac

Source: SEC EDGAR · 8-K filed Feb 28, 2020

More decks from Biohaven Pharmaceutical Holding Co Ltd